| Date Filed | Type | Description |
| 10/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/28/2023 |
8-K
| Quarterly results |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 07/13/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 06/01/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/15/2023 |
8-K
| Quarterly results |
| 05/05/2023 |
4
| WEAVER GREGORY L (Director) has filed a Form 4 on ATOSSA THERAPEUTICS, INC.|
Txns:
| Granted 125,000 options to buy
@ $0.662, valued at
$82.8k
|
|
| 05/05/2023 |
4
| Remmel H. Lawrence (Director) has filed a Form 4 on ATOSSA THERAPEUTICS, INC.|
Txns:
| Granted 125,000 options to buy
@ $0.662, valued at
$82.8k
|
|
| 05/05/2023 |
4
| Steinhart Richard I (Director) has filed a Form 4 on ATOSSA THERAPEUTICS, INC.|
Txns:
| Granted 125,000 options to buy
@ $0.662, valued at
$82.8k
|
|
| 05/05/2023 |
4
| Chen Shu-Chih (Director) has filed a Form 4 on ATOSSA THERAPEUTICS, INC.|
Txns:
| Granted 125,000 options to buy
@ $0.662, valued at
$82.8k
|
|
| 05/05/2023 |
4
| Galli Stephen J (Director) has filed a Form 4 on ATOSSA THERAPEUTICS, INC.|
Txns:
| Granted 125,000 options to buy
@ $0.662, valued at
$82.8k
|
|
| 05/04/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 04/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/26/2023 |
8-K
| Quarterly results |
| 04/04/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 03/30/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/22/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/22/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 03/13/2023 |
8-K
| Other Events Interactive Data |
| 03/06/2023 |
4
| QUAY STEVEN C (President & CEO) has filed a Form 4 on ATOSSA THERAPEUTICS, INC.|
Txns:
| Granted 1,873,100 options to buy
@ $0.72, valued at
$1.3M
|
|
| 03/06/2023 |
4
| Guse Kyle (CFO, Gen Counsel and Secretary) has filed a Form 4 on ATOSSA THERAPEUTICS, INC.|
Txns:
| Granted 557,900 options to buy
@ $0.72, valued at
$401.7k
|
|
| 11/07/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/07/2022 |
8-K
| Quarterly results |
| 10/07/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/08/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/08/2022 |
8-K
| Quarterly results |
| 07/08/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 07/07/2022 |
8-K
| Quarterly results |
| 07/01/2022 |
8-K
| Quarterly results |
| 06/06/2022 |
8-K
| Quarterly results |
| 05/16/2022 |
4
| Chen Shu-Chih (Director) has filed a Form 4 on ATOSSA THERAPEUTICS, INC.|
Txns:
| Granted 50,000 options to buy
@ $0.93, valued at
$46.5k
|
|
| 05/16/2022 |
4
| Galli Stephen J (Director) has filed a Form 4 on ATOSSA THERAPEUTICS, INC.|
Txns:
| Granted 50,000 options to buy
@ $0.93, valued at
$46.5k
|
|
|